These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29512893)

  • 1. Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis.
    Kirkham HS; Staskon F; Hira N; McLane D; Kilgore KM; Parente A; Kim S; Sawicki GS
    Pediatr Pulmonol; 2018 Jun; 53(6):720-727. PubMed ID: 29512893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pharmacy services on cystic fibrosis medication adherence.
    Zobell JT; Schwab E; Collingridge DS; Ball C; Nohavec R; Asfour F
    Pediatr Pulmonol; 2017 Aug; 52(8):1006-1012. PubMed ID: 28608652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
    Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
    J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.
    Sawicki GS; Ayyagari R; Zhang J; Signorovitch JE; Fan L; Swallow E; Latremouille-Viau D; Wu EQ; Shi L
    Pediatr Pulmonol; 2013 Oct; 48(10):954-61. PubMed ID: 23255309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pharmacy technicians as part of an integrated health-system pharmacy team on improvement of medication access in the care of cystic fibrosis patients.
    Zobell JT; Moss J; Heuser SM; Asfour F
    Pediatr Pulmonol; 2020 Dec; 55(12):3351-3357. PubMed ID: 32876997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of long-term medication adherence with cystic fibrosis: An integrated approach.
    Platt T; Kormelink LN; Autry EB; Rossoll SJ; Kuhn RJ
    Pediatr Pulmonol; 2024 Feb; 59(2):458-464. PubMed ID: 38018665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dornase alfa for cystic fibrosis.
    Yang C; Chilvers M; Montgomery M; Nolan SJ
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy performance while providing continuous medication monitoring.
    Doucette WR; McDonough RP; Herald F; Goedken A; Funk J; Deninger MJ
    J Am Pharm Assoc (2003); 2017; 57(6):692-697. PubMed ID: 28844583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health insurance and use of recommended routine care in adults with cystic fibrosis.
    Li SS; Hayes D; Tobias JD; Morgan WJ; Tumin D
    Clin Respir J; 2018 May; 12(5):1981-1988. PubMed ID: 29356436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study.
    Rozov T; Silva FA; Santana MA; Adde FV; Mendes RH;
    Rev Paul Pediatr; 2013 Dec; 31(4):420-30. PubMed ID: 24473945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to therapies in cystic fibrosis: a targeted literature review.
    Narayanan S; Mainz JG; Gala S; Tabori H; Grossoehme D
    Expert Rev Respir Med; 2017 Feb; 11(2):129-145. PubMed ID: 28107795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal association between medication adherence and lung health in people with cystic fibrosis.
    Eakin MN; Bilderback A; Boyle MP; Mogayzel PJ; Riekert KA
    J Cyst Fibros; 2011 Jul; 10(4):258-64. PubMed ID: 21458391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers.
    Glauser TA; Nevins PH; Williamson JC; Abdolrasulnia M; Salinas GD; Zhang J; Debonnett L; Riekert KA
    Pediatr Pulmonol; 2012 May; 47(5):434-40. PubMed ID: 22495970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating self-efficacy, disease knowledge and adherence to treatment in adolescents with cystic fibrosis.
    Faint NR; Staton JM; Stick SM; Foster JM; Schultz A
    J Paediatr Child Health; 2017 May; 53(5):488-493. PubMed ID: 28186386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of medication synchronization programs on proportion of days covered (PDC) scores and Medicare Part D medication-related adherence metrics.
    Bernard K; Cowles B; McCall K; Henningsen RM; O'Toole M; Tu C
    J Am Pharm Assoc (2003); 2019; 59(3):343-348. PubMed ID: 30940515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.